Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2002 May;3(5):794-7.

Rasagiline. Teva Pharmaceutical.

Author information

1
Department of Neurology, Charite-Virchow, Berlin, Germany. andreas.kupsch@charite.de

Abstract

Rasagiline is a selective and potent irreversible MAO(B) inhibitor which is under development by Teva for the treatment of neurological diseases. Rasagiline is in phase III trials in the US, Canada and Europe for Parkinson's disease (PD) and has completed phase II trials in Israel and Hungary. Teva planned to submit a filing in 2002 and expected to launch rasagiline in 2003. Lundbeck acquired European development and commercialization rights to rasagiline in November 1999 and, in September 2001, the company reported that it planned to file an NDA in 2003. In March 2002, analysts at Morgan Stanley Dean Witter predicted that H Lundbeck would make sales of rasagiline of DKr 100 million in 2003, rising to DKr 300 million in 2008. In the same month, launch was predicted in 2004/2005 for the PD indication, and 2005/2006 for the AD indication, by analysts at Deutsche Banc Alex Brown.

PMID:
12090555
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center